ArticleBMC oral health2025
A novel selective medium Sucrose-Bacitracin agar 10 for accurate isolation and identification of Streptococcus mutans.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo develop and evaluate Sucrose-Bacitracin agar with 10% sucrose (SB-10), a novel selective medium designed to enhance the isolation and identification of Streptococcus mutans, a key cariogenic pathogen in dental caries.
methodsSB-10 was compared to Mitis Salivarius Bacitracin agar with 20% sucrose (MSB-20) for its ability to support S. mutans growth, promote distinctive colony morphology, and differentiate it from other oral bacteria. Sugar particle formation was assessed using wild-type and mutant strains of S. mutans lacking glucosyltransferases B and C (GtfB and GtfC). Liquid chromatography was performed to characterize the sugar particles around colonies. The specificity and clinical utility of SB-10 were further assessed by culturing clinical saliva samples and confirming S. mutans colonies via 16S rRNA sequencing.
resultsSB-10 supported robust S. mutans growth with larger colonies and distinctive sugar particle formation compared to MSB-20. GtfB and GtfC were essential for sugar particle deposition around colonies. SB-10 demonstrated high specificity by suppressing the growth of non-target oral bacteria and accurately isolating S. mutans from clinical saliva samples, with all colonies confirmed as S. mutans via 16S rRNA sequencing.
conclusionsSB-10 is a novel selective medium that enhances the isolation and identification of S. mutans, characterized by unique sugar particles deposition and colony morphology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.